Tirzepatide approved for OSA in the US but not the EU yet
In December 2024, the FDA approved Zepbound (tirzepatide) for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity — the first GLP-1-class drug approved specifically for sleep apnea. The European Medicines Agency has not yet granted the same indication; the regulatory paths in the two regions are different.
What OSA is
Obstructive sleep apnea is a condition where the upper airway collapses during sleep, interrupting breathing. It's graded by the apnea-hypopnea index (AHI) — number of apnea/hypopnea events per hour of sleep:
- Mild: 5–15 events/hour.
- Moderate: 15–30 events/hour.
- Severe: >30 events/hour.
Obesity is the most common reversible cause of OSA. Soft-tissue accumulation around the airway, plus reduced lung volumes from chest-wall fat, contribute to airway collapse during sleep.
SURMOUNT-OSA: what the trial showed
Lilly's Phase 3 trial in adults with obesity and moderate-to-severe OSA:
| Trial arm | Population | AHI reduction at 52 weeks | Weight loss |
|---|---|---|---|
| SURMOUNT-OSA-1 | OSA + obesity, no PAP therapy | −25 events/hour | ~18% body weight |
| SURMOUNT-OSA-2 | OSA + obesity, on PAP therapy | −30 events/hour | ~20% body weight |
For context, a 25-event/hour reduction is enough to move many moderate OSA patients to mild or normal AHI. Combined with PAP therapy, the effect is even larger.
The mechanism
Tirzepatide doesn't directly affect the airway; it works through weight loss:
- Reduced parapharyngeal fat decreases airway compression during sleep.
- Reduced abdominal and chest-wall fat improves lung volumes and reduces airway collapsibility.
- Improved sleep architecture through reduced inflammation and metabolic improvements.
Studies have shown that significant weight loss (10–15%+) typically produces a measurable AHI reduction. Tirzepatide's aggressive weight loss accelerates this process.
The US approval
FDA approval covers:
- Adults with moderate-to-severe OSA (AHI ≥15).
- And obesity (BMI ≥30, or BMI ≥27 with weight-related comorbidities).
- As Zepbound (the brand name for tirzepatide in obesity/weight indications).
- Same dosing as Zepbound for obesity: titration from 2.5 mg → 15 mg weekly.
This means the same drug, same dosing schedule, but a different label-supported indication and (significantly) different insurance coverage. Some insurance plans that don't cover Zepbound for obesity will cover it for OSA — the regulatory indication matters for coverage.
The EU situation
As of 2026, the EMA has not yet approved tirzepatide for OSA. The reasons for the lag:
- Different regulatory pace. EMA review timelines differ from FDA's; same data, different rate of decision.
- Different evidentiary standards. EMA sometimes requires additional studies or local-population data.
- Different commercial priorities. Lilly's EU submission strategy is somewhat independent of US.
- Existing EU obesity indication. Mounjaro is approved for T2D in the EU; Mounjaro for obesity has been approved more recently. OSA may come as a follow-on.
Expected EU OSA approval: 2026–2027 timeline, but uncertain.
For US patients
The OSA approval means:
- Insurance coverage may be available for tirzepatide on the OSA indication where it wasn't available for obesity alone.
- Clinical justification for the prescription is OSA-based, not weight-loss-based.
- Sleep medicine clinicians are increasingly prescribing tirzepatide as a primary OSA therapy alongside or in place of PAP.
Does this mean I can stop my CPAP?
Probably not, at least initially. Most clinicians recommend:
- Continue PAP therapy during the weight-loss phase.
- Re-evaluate with sleep study after significant weight loss (typically 10%+ of body weight).
- Reduce PAP pressure or simplify therapy as AHI decreases.
- Discontinue PAP only when sleep study confirms AHI <5 (resolution) and clinical symptoms have improved.
The decision is gradual and clinician-guided.
Other GLP-1s for OSA
Semaglutide (Wegovy) hasn't been studied as rigorously for OSA, but pre-existing weight-loss trials have shown AHI improvements as a secondary outcome. A formal Wegovy-for-OSA indication may follow, though Novo Nordisk has not announced specific Phase 3 plans for OSA.
Retatrutide and CagriSema may also pursue OSA indications if they reach approval — the weight-loss-driven mechanism is generalizable.
What this signals
The Zepbound OSA approval is the first of what will likely be many "weight loss enables resolution of comorbid condition" indications:
- OSA — done (US).
- MASH (steatohepatitis) — semaglutide accelerated approval in March 2025; tirzepatide and survodutide pursuing.
- Heart failure with preserved ejection fraction (HFpEF) — semaglutide SELECT-HF results pending.
- Osteoarthritis (knee) — semaglutide STEP-9 showed pain reduction; indication pursued.
- Cardiovascular events (MACE) — semaglutide SELECT was the first; expanded indications likely.
Each new indication reframes the drug from "weight loss" to "treatment for X with weight loss as mechanism" — which often changes insurance coverage and patient framing.
FAQ
Does the OSA approval mean tirzepatide is better for OSA than semaglutide?
It means tirzepatide has Phase 3 data and FDA approval; semaglutide has secondary-endpoint data but no formal OSA indication yet. Functionally, both produce weight loss that improves OSA; the regulatory difference is current state, not biology.
I have OSA but my BMI is 25. Will tirzepatide help?
Not approved at your BMI for OSA; obesity is a co-requirement for the indication. Underlying weight-loss mechanism may still help, but the indication doesn't cover normal-BMI OSA.
How long until I can stop CPAP after starting tirzepatide?
Variable. Typical timeline: 6–12 months of weight loss followed by sleep study. Some patients can taper PAP pressure earlier; others need PAP indefinitely depending on anatomy.
Is the OSA approval changing tirzepatide's pricing or availability?
Not directly. Same Zepbound product, same supply chain. Insurance coverage may expand because the indication is more clinically substantial in some plans' formulary review.
Related reading
Track approval status by region
Peptide Protocol shows current regulatory status for every drug across regions — so you know what's approved where, when.
Get the iPhone app →Informational and educational only. Not medical advice. Consult a licensed clinician before starting, changing, or stopping any peptide protocol. Mentions of investigational, compounded, or research-use peptides are for informational purposes; many such substances are not FDA-approved for human use.